Previous 10 | Next 10 |
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announce...
Cellectis ( NASDAQ: CLLS ) on Thursday launched a global offering of USD22 million of its American Depositary Shares. Shares -17.2% at $2.70 after the bell. The underwriting agreement is expected to be entered into by Cellectis, Jefferies and Barclays Capital. The glob...
Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...
French biotech Cellectis S.A. ( NASDAQ: CLLS ) ( OTCPK:CMVLF ) added ~9% pre-market Monday after announcing changes to the certain financial terms of its partnership with cancer-focused biotech Cytovia Therapeutics. The amendments relate to the $20M convertible note Cytovia is...
NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it has amended certai...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Calyxt (NASDAQ: CLXT ) stock is rocketing higher on Tuesday after the company signed a merger agreement with Cibus Global . Calyxt and Cibus Global both operate in the agriculture-based...
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company (ȁ...
Primera Therapeutics and French biotech Cellectis ( NASDAQ: CLLS ) on Thursday said they would collaborate to develop therapies for mitochondrial diseases. Primera and CLLS will work collaboratively to edit mutations of the mitochondrial DNA to treat the root cause of associated cause...
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Following the formation of Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and Mayo Clinic, comes the launch of their first start-up, Primera Therapeutics, Inc. (Primera). Cellectis (Euronext Growth: ALCLS -...
Clinical-stage biotech Cellectis ( NASDAQ: CLLS ) on Wednesday said it had entered into a €40M credit agreement with the European Investment Bank (EIB). CLLS will use the credit facility to support the development of its CAR T-cell product candidates, the company said in a st...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...